BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 8898956)

  • 1. Differential modulation of cyclin-dependent kinase inhibitor p27Kip1 by negative signaling via the antigen receptor of B cells and positive signaling via CD40.
    Han H; Nomura T; Honjo T; Tsubata T
    Eur J Immunol; 1996 Oct; 26(10):2425-32. PubMed ID: 8898956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of the cyclin-dependent kinase inhibitor p27Kip1 in negative signaling through the antigen-receptor of B lymphocytes.
    Han H; Nomura T; Honjo T; Tsubata T
    Leukemia; 1997 Apr; 11 Suppl 3():367-9. PubMed ID: 9209392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TGF-beta 1 induces the cyclin-dependent kinase inhibitor p27Kip1 mRNA and protein in murine B cells.
    Kamesaki H; Nishizawa K; Michaud GY; Cossman J; Kiyono T
    J Immunol; 1998 Jan; 160(2):770-7. PubMed ID: 9551912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
    Coppock DL; Buffolino P; Kopman C; Nathanson L
    Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of c-fos inhibits down-regulation of a cyclin-dependent kinase-2 inhibitor p27Kip1 in splenic B cells activated by surface Ig cross-linking.
    Kobayashi K; Phuchareon J; Inada K; Tomita Y; Koizumi T; Hatano M; Miyatake S; Tokuhisa T
    J Immunol; 1997 Mar; 158(5):2050-6. PubMed ID: 9036948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of p27Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells.
    Tsihlias J; Zhang W; Bhattacharya N; Flanagan M; Klotz L; Slingerland J
    Oncogene; 2000 Feb; 19(5):670-9. PubMed ID: 10698512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.
    Orend G; Hunter T; Ruoslahti E
    Oncogene; 1998 May; 16(20):2575-83. PubMed ID: 9632134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retinoic acid-mediated growth arrest of EBV-immortalized B lymphocytes is associated with multiple changes in G1 regulatory proteins: p27Kip1 up-regulation is a relevant early event.
    Zancai P; Cariati R; Rizzo S; Boiocchi M; Dolcetti R
    Oncogene; 1998 Oct; 17(14):1827-36. PubMed ID: 9778049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limiting amounts of p27Kip1 correlates with constitutive activation of cyclin E-CDK2 complex in HTLV-I-transformed T-cells.
    Cereseto A; Washington Parks R; Rivadeneira E; Franchini G
    Oncogene; 1999 Apr; 18(15):2441-50. PubMed ID: 10229195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical role for p27Kip1 in cell cycle arrest after androgen depletion in mouse mammary carcinoma cells (SC-3).
    Menjo M; Kaneko Y; Ogata E; Ikeda K; Nakanishi M
    Oncogene; 1998 Nov; 17(20):2619-27. PubMed ID: 9840925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CaMK-II inhibition reduces cyclin D1 levels and enhances the association of p27kip1 with Cdk2 to cause G1 arrest in NIH 3T3 cells.
    Morris TA; DeLorenzo RJ; Tombes RM
    Exp Cell Res; 1998 May; 240(2):218-27. PubMed ID: 9596994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased p27Kip1 cyclin-dependent kinase inhibitor gene expression following anti-IgM treatment promotes apoptosis of WEHI 231 B cells.
    Wu M; Bellas RE; Shen J; Yang W; Sonenshein GE
    J Immunol; 1999 Dec; 163(12):6530-5. PubMed ID: 10586045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of p27Kip1 in the G1- and S/G2-phase lengthening mediated by glucocorticoids in normal human lymphocytes.
    Baghdassarian N; Peiretti A; Devaux E; Bryon PA; Ffrench M
    Cell Growth Differ; 1999 Jun; 10(6):405-12. PubMed ID: 10392902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immature stage B cells enter but do not progress beyond the early G1 phase of the cell cycle in response to antigen receptor signaling.
    Carman JA; Wechsler-Reya RJ; Monroe JG
    J Immunol; 1996 Jun; 156(12):4562-9. PubMed ID: 8648097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of cyclin A and p27 in anti-IgM induced G1 growth arrest of murine B-cell lymphomas.
    Ezhevsky SA; Toyoshima H; Hunter T; Scott DW
    Mol Biol Cell; 1996 Apr; 7(4):553-64. PubMed ID: 8730099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formation of p27-CDK complexes during the human mitotic cell cycle.
    Soos TJ; Kiyokawa H; Yan JS; Rubin MS; Giordano A; DeBlasio A; Bottega S; Wong B; Mendelsohn J; Koff A
    Cell Growth Differ; 1996 Feb; 7(2):135-46. PubMed ID: 8822197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc.
    Vlach J; Hennecke S; Alevizopoulos K; Conti D; Amati B
    EMBO J; 1996 Dec; 15(23):6595-604. PubMed ID: 8978686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproliferative function of p27kip1 is frequently inhibited in highly malignant Burkitt's lymphoma cells.
    Barnouin K; Fredersdorf S; Eddaoudi A; Mittnacht S; Pan LX; Du MQ; Lu X
    Oncogene; 1999 Nov; 18(46):6388-97. PubMed ID: 10597239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inducible pRb2/p130 expression and growth-suppressive mechanisms: evidence of a pRb2/p130, p27Kip1, and cyclin E negative feedback regulatory loop.
    Howard CM; Claudio PP; De Luca A; Stiegler P; Jori FP; Safdar NM; Caputi M; Khalili K; Giordano A
    Cancer Res; 2000 May; 60(10):2737-44. PubMed ID: 10825149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming growth factor beta-induced activation of cyclin E-cdk2 kinase and down-regulation of p27Kip1 in C3H 10T1/2 mouse fibroblasts.
    Ravitz MJ; Yan S; Herr KD; Wenner CE
    Cancer Res; 1995 Apr; 55(7):1413-6. PubMed ID: 7882344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.